期刊文献+

人β淀粉样蛋白1-42在大肠杆菌中的表达纯化及鉴定

Expression of human β amyloid 1-42 protein in E.coli and its purification and identification
暂未订购
导出
摘要 目的在大肠杆菌中表达人源性β淀粉样蛋白1-42(Aβ1-42),纯化表达蛋白并进行Western blot鉴定。方法根据Gen Bank中人源性Aβ1-42编码序列,分为3个片段人工合成,经退火延伸为全长dsDNA序列,酶切后连接至表达质粒pET-28a(+)构建为重组质粒pET-28a-Aβ1-42,转化至大肠杆菌BL21株中,筛选高表达株,诱导表达,利用Ni+株亲和纯化表达蛋白,SDS-PAGE后,转印PVDF膜,进行Western blot鉴定。结果获得纯化的大肠杆菌表达蛋白Aβ1-42,表达形式为包涵体,经Western blot鉴定为人源性Aβ1-42蛋白。结论本研究获得了纯化的Aβ1-42蛋白,为下一步采用Aβ1-42标记该蛋白作为诊断分子奠定了基础。 Objective To express the human β amyloid 1-42 protein in E. coil,purify the protein and identify it by Western blot. Methods The gene fragment coding the human β amyloid 1-42 region was synthesized with 3 fragments and annealed,then digested by restrictive enzyme and linked into the expression plasmid pET-28a(+) to construct the expression plasmid pET-28a-Aβ1-42. After identified by restrictive enzyme and DNA sequencing, the expression plasmid was transformed into E. coli BL21 strain,the high expression strain was selected and induced,the expressed recombinant protein was purified by using Ni+ affinity chromatograph, and the purified protein was transferred to PVDF membrane after SDS PAGE, and then identified by Western blot. Results The expressed recombinant protein was purified, it was expressed as inclusion body form,and the expressed protein was identified to be human β amyloid 1-42 protein by Western blot. Conclusion The human β amyloid 1-42 protein is expressed and purified,and this work provides a basis and material for Aβ1-42 protein marked and used as molecular diagnosis tool for Alzheimer's disease.
出处 《重庆医学》 CAS CSCD 北大核心 2010年第3期262-264,267,I0001,共5页 Chongqing medicine
基金 第三军医大学校管课题资助项目
关键词 β淀粉样蛋白1-42 阿尔茨海默病 蛋白表达 amyloid 1-42 Alzheimer' s disease protein expression
  • 相关文献

参考文献10

  • 1王小林,王永红.电刺激小脑顶核在阿尔茨海默病治疗中的可能价值[J].重庆医学,2008,37(19):2242-2244. 被引量:2
  • 2王文霞,臧卫周,冯艳,徐军.阿尔茨海默病的影响因素研究[J].医药论坛杂志,2005,26(17):42-43. 被引量:3
  • 3吴芳,蔡志友,晏勇.阿尔茨海默病糖代谢源性发病机制研究进展[J].重庆医学,2008,37(17):1999-2001. 被引量:4
  • 4Poduslo JF, Curran GL, Gill JS. Putreseine-modified NGF: Bioactivity, pharmaeokinetics, blood-brain/nerve barrier permeability and nervous system biodistribution [J]. J Neurochem, 1998,71 : 1651.
  • 5侯倩.阿尔茨海默病的诊治进展[J].山东医药,2008,48(23):111-112. 被引量:12
  • 6Apostolova I.G,Dinov ID,Dutton RA, et al. 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease[J]. Brain, 2006, 129 (11):2867.
  • 7Jack CR, Shiung MM, Weigand SD, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI[J]. Neurology,2005,65(8):1227.
  • 8Kayed R, Head E, Thompson J, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis[J]. Science, 2003,300 : 486.
  • 9卢圣栋.现代分子生物学技术[M].2版.北京:中国协和医科大学出版社,1999:458-463.
  • 10Li M, He S. Purification and characterization of recombinant human interleukin-29 expressed in Escherichia coli [J]. J Biotechnol, 2006,122 : 334.

二级参考文献52

  • 1张镛,刘振芳,杜怡峰,刘振华,李建峰,解增金,邢涛.血管性痴呆和Alzheimer病的载脂蛋白E基因多态性研究[J].山东医药,2004,44(22):1-2. 被引量:3
  • 2朱正禹,毕建忠,许顺良,王晓云,谢兆宏,杨萧荟.阿司匹林治疗前后Alzheimer病患者外周血细胞因子基因表达变化[J].山东医药,2004,44(22):3-5. 被引量:2
  • 3李霞,李凌云.安理申治疗血管性痴呆50例[J].山东医药,2005,45(23):56-56. 被引量:2
  • 4Leboeuf R. Homoeysteine and Alzheimer's disease. J Am Diet Assoc ,2003,103 ( 3 ) :304-7.
  • 5Nilsson K, Gustafson L, Hultberg B. Plasma homocysteine concentration relates to the severity but not to the duration of Alzheimer's disease, Int J Geriatr Psychiatry,2004, 19(7) :666-72.
  • 6Dwyer BE, Raina AK, Perry G, Smith MA. Homocysteine and Alzheimer's disease: a modifiable risk? Free Radie Biol Med,2004,36( 11 ) :1471-5.
  • 7Anello G, Gueant Rodriguez RM, Bosco P, et al. Homocysteine and methylenetetrahydrofolate reductase polymorphism in Alzheimer's disease. Neuroreport,2004,15 (5) :859-61.
  • 8Wakutani Y, Kowa H, Kusumi M, et al. Genetic analysis of vascular factors in Alzheimer's disease. Ann N Y Acad Sci,2002 ,977:232-8.
  • 9Storey SG, Suryadevara V, Aronow WS, et al. Association of plasma homocysteine in elderly persons with atherosclerotic vascular disease and dementia, athcrosclerotic vascular disease without dementia, dementia without athcrosclerotic vascular disease, and no dementia or atherosclerotic vascular disease. J Gerontol A Biol Sci Med Sci,2003,58(12) :1135-6.
  • 10Malouf M, Grimley E J, Areosa SA. Folic acid with or without vitamin B12 for cognition and dementia. Cochrane Database Syst Rev, 2003, (4) :4514.

共引文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部